H.C. Wainwright initiated coverage of Beam Therapeutics with a Buy rating and $80 price target. Beam’s base editing platform may overcome limitations of existing approaches and expand the potential of genetic medicines, the analyst tells investors in a research note. The firm says near-term catalysts, including initial first-in-human data with BEAM-101 in the second half of 2024, should further validate the pipeline.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BEAM:
- Cathie Wood’s ARK Investment buys 60K shares of Beam Therapeutics today
- Cathie Wood’s ARK Investment buys 160K shares of Beam Therapeutics today
- Beam Therapeutics selloff on CFO exit misplaced, says JPMorgan
- Beam Therapeutics Announces CFO Terry-Ann Burrell’s Resignation
- Beam Therapeutics Announces Transition of Chief Financial Officer